Literature DB >> 16365853

A syndrome of irreversible leukoencephalopathy following pediatric allogeneic bone marrow transplantation.

A Yuriko Minn1, Paul G Fisher, Patrick D Barnes, Gary V Dahl.   

Abstract

BACKGROUND: Despite decreases in overall mortality following bone marrow transplantation (BMT), a number of complications such as neurotoxicity have been described and often associated with immunosuppressive agents. The syndrome of reversible posterior leukoencephalopathy has been described in patients receiving cyclosporin and FK-506. We report here a subset of children who developed a syndrome of previously undescribed irreversible leukoencephalopathy following allogeneic BMT. PATIENTS AND METHODS: Between 1996 and 2002, 138 pediatric patients received an allogeneic BMT at Lucile Salter Packard Children's Hospital at Stanford. Six cases of irreversible leukoencephalopathy were observed. Cases were defined as children who exhibited progressive and continued, severe neurologic deterioration lasting greater than 2 weeks and consistent with non-localizing, central nervous system abnormalities. Medical records and magnetic resonance images (MRIs) were reviewed.
RESULTS: Median age of the affected patients at BMT was 7.8 years. All six received cyclosporine, and [corrected] one had elevated drug levels. Encephalopathy occurred at a median of 53 days (range 14-77) following BMT. Symptoms at onset of leukoenceophalopathy included confusion and altered mental status, sluggish pupillary responses, abnormal movements, and seizures. Two patients died during their neurologic decline. Four patients remain alive with persistent encephalopathy. MRI showed abnormalities in all patients including periventricular or subcortical white matter involvement in all, and basal ganglia lesions in three.
CONCLUSIONS: We report a syndrome of irreversible neurologic deficits and cerebral white matter abnormalities following allogeneic BMT, yet not associated with elevated cyclosporin levels. A precise mechanism for this syndrome is lacking and warrants further consideration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16365853     DOI: 10.1002/pbc.20731

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  5 in total

1.  An intensive care approach to posterior reversible encephalopathy syndrome (PRES): An analysis of 7 cases.

Authors:  İsmail Demirel; Burçin Salih Kavak; Ayşe B Özer; Mustafa K Bayar; Ömer L Erhan
Journal:  J Turk Ger Gynecol Assoc       Date:  2014-12-01

2.  Thrombomodulin blocks calcineurin inhibitor-induced vascular permeability via inhibition of Src/VE-cadherin axis.

Authors:  T Ikezoe; J Yang; C Nishioka; K Umezawa; A Yokoyama
Journal:  Bone Marrow Transplant       Date:  2016-09-19       Impact factor: 5.483

3.  High incidence of severe cyclosporine neurotoxicity in children affected by haemoglobinopaties undergoing myeloablative haematopoietic stem cell transplantation: early diagnosis and prompt intervention ameliorates neurological outcome.

Authors:  Anna Noè; Barbara Cappelli; Alessandra Biffi; Robert Chiesa; Ilaria Frugnoli; Erika Biral; Valentina Finizio; Cristina Baldoli; Paolo Vezzulli; Fabio Minicucci; Giovanna Fanelli; Rossana Fiori; Fabio Ciceri; Maria Grazia Roncarolo; Sarah Marktel
Journal:  Ital J Pediatr       Date:  2010-02-06       Impact factor: 2.638

4.  Lysergic acid amide-induced posterior reversible encephalopathy syndrome with status epilepticus.

Authors:  Stephane Legriel; Fabrice Bruneel; Odile Spreux-Varoquaux; Aurelie Birenbaum; Marie Laure Chadenat; François Mignon; Nathalie Abbosh; Matthieu Henry-Lagarrigue; Laure Revault D'Allonnes; Pierre Guezennec; Gilles Troche; Jean Pierre Bedos
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

5.  High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.

Authors:  J R Long-Boyle; K G Green; C G Brunstein; Q Cao; J Rogosheske; D J Weisdorf; J S Miller; J E Wagner; P B McGlave; P A Jacobson
Journal:  Bone Marrow Transplant       Date:  2010-04-12       Impact factor: 5.483

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.